Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission

Mine Harada, Koichi Akashi, Shin Hayashi, Tetsuya Eto, Yasushi Takamatsu, Takanori Teshima, Yuichi Hirota, Shuichi Taniguchi, Koji Nagafuji, Shinichi Mizuno, Hisashi Gondo, Yoshiyuki Niho

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

We conducted a clinical trial to increase the chemosensitivity of residual leukemic cells by combining G-CSF to marrow-ablative chemotherapy, including cytosine arabinoside (Ara-C); and facilitated by autologous blood cell transplantation (ABCT) for treatment of acute myelogenous leukemia (AML) in first complete remission. A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high- dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy: At a median follow-up time of 44.5 months, the probability of 5-year event-free survival was 74.5% with only three leukemic relapses. This preliminary observation suggests the effectiveness of G-CSF-combined conditioning and ABCT as a post-remission therapy for AML.

Original languageEnglish
Pages (from-to)297-301
Number of pages5
JournalInternational Journal of Hematology
Volume66
Issue number3
Publication statusPublished - Oct 1 1997
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission'. Together they form a unique fingerprint.

  • Cite this